157665-51-5

Basic information

• Product Name: 3-FLUORO-4-NITROBENZOYL CHLORIDE
• Synonyms: 3-FLUORO-4-NITROBENZOYL CHLORIDE;4-(Chlorocarbonyl)-2-fluoronitrobenzene, 4-(Chloroformyl)-2-fluoronitrobenzene
• CAS NO: 157665-51-5
• Molecular Formula: C₇H₃ClFNO₃
• Molecular Weight: 203.56
• Mol File: 157665-51-5.mol
• Article Data: 31

Chemical Properties

• Melting Point: 23-25
• Appearance: /
• CAS DataBase Reference: 3-FLUORO-4-NITROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-NITROBENZOYL CHLORIDE(157665-51-5)
• EPA Substance Registry System: 3-FLUORO-4-NITROBENZOYL CHLORIDE(157665-51-5)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 157665-51-5(Hazardous Substances Data)

Usage

Uses

3-Fluoro-4-nitrobenzoyl chloride is used as a reactant or a reagent in various organic reactions.

Upstream product

• 79-37-8 oxalyl dichloride 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 

Downstream Products

• 855869-58-8 2-(3-cyano-4-fluoro-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [2-fluoro-4-(pyrrolidine-1-carbonyl)-phenyl]-amide 
• 218298-94-3 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl-aminocarbonyl]pyrazole 
• 209960-85-0 (4-amino-3-fluorophenyl)pyrrolidin-1-ylmethanone 
• 1124215-02-6 (3-fluoro-4-nitrophenyl)(3-(fluoromethyl)piperazin-1-yl)methanone 
• 85803-26-5 di-tert-butyl N-(3-fluoro-4-nitrobenzoyl)-l-glutamate 
• 159390-15-5 4-amino-3-fluorobenzophenone 
• 952521-83-4 4-amino-3-(tetrahydrofuran-3-yloxy)-benzamide 
• 952521-84-5 3-(tetrahydrofuran-3-yloxy)-4-(thieno[3,2-d]pyrimidin-4-ylamino)-benzamide 
• 2006314-49-2 (R)-1-(3-fluoro-4-nitrophenyl)ethan-1-ol 
• 72802-25-6 3-fluoro-4-nitroacetophenone 

Relevant articles and documents

Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors

Cathepsin K is a major drug target for osteoporosis and related-bone disorders. Using a combination of virtual combinatorial chemistry, QSAR modeling, and molecular docking studies, a series of cathepsin K inhibitors based on N-(functionalized benzoyl)-homocycloleucyl-glycinonitrile scaffold was developed. In order to avoid previous problems of cathepsin K inhibitors associated with lysosomotropism of compounds with basic character that resulted in off-target effects, a weakly- to nonbasic moiety was incorporated into the P3 position. Compounds 5, 6, and 9 were highly selective for cathepsin K when compared with cathepsins L and S, with the Ki values in the 10-30 nM range. The kinetic studies revealed that the new compounds exhibited reversible tight binding to cathepsin K, while the X-ray structural studies showed covalent and noncovalent binding between the nitrile group and the catalytic cysteine (Cys25) site.

sEH Inhibitor or pharmaceutically acceptable composition thereof as well as preparation method and application thereof

The invention provides sEH inhibitor or a pharmaceutically acceptable composition and a preparation method and application thereof, and belongs to the technical field of medicines. sEH Inhibitor or a pharmaceutically acceptable composition thereof according to the present invention is provided, and the sEH inhibitor has the structure shown I. sEH Inhibitor provided by the invention can stabilize an endogenous substance epoxy fatty acid with wide physiological activity, has a strong inhibition effect on human recombinant sEH, and can be used for regulating the generation of a plurality of pro-inflammatory cytokines. The invention relieves the stress of endoplasmic reticulum, prevents or reverses the dysfunction of endothelial dysfunction, stabilizes mitochondria function multiple action mechanisms to obviously relieve neuropathic pain, and can effectively avoid adverse reactions related to the target spot. Furthermore, the sEH inhibitor structure provided by the invention does not contain free carboxyl groups, can avoid adverse reactions such as gastrointestinal irritation caused by oral administration, and is small in adverse reaction, high in bioavailability, excellent in analgesic effect and small in administration amount.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.